Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women

Show full item record



Permalink

http://hdl.handle.net/10138/321757

Citation

Louvanto , K , Eriksson , T , Gray , P , Apter , D , Baussano , I , Bly , A , Harjula , K , Heikkila , K , Hokkanen , M , Huhtinen , L , Ikonen , M , Karttunen , H , Nummela , M , Soderlund-Strand , A , Veivo , U , Dillner , J , Elfstöm , M , Nieminen , P & Lehtinen , M 2020 , ' Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women ' , International Journal of Cancer , vol. 147 , no. 2 , pp. 440-447 . https://doi.org/10.1002/ijc.32802

Title: Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women
Author: Louvanto, Karolina; Eriksson, Tiina; Gray, Penelope; Apter, Dan; Baussano, Iacopo; Bly, Anne; Harjula, Katja; Heikkila, Kaisa; Hokkanen, Mari; Huhtinen, Leila; Ikonen, Marja; Karttunen, Heidi; Nummela, Mervi; Soderlund-Strand, Anna; Veivo, Ulla; Dillner, Joakim; Elfstöm, Miriam; Nieminen, Pekka; Lehtinen, Matti
Contributor organization: HUS Gynecology and Obstetrics
University Management
Department of Obstetrics and Gynecology
University of Helsinki
Date: 2020-07-15
Language: eng
Number of pages: 8
Belongs to series: International Journal of Cancer
ISSN: 0020-7136
DOI: https://doi.org/10.1002/ijc.32802
URI: http://hdl.handle.net/10138/321757
Abstract: Less frequent cervical cancer screening in human papillomavirus (HPV) vaccinated birth cohorts could produce considerable savings without increasing cervical cancer incidence and loss of life-years. We report here the baseline findings and interim results of safety and accuracy of infrequent screening among HPV16/18 vaccinated females. The entire 1992-1994 birth-cohorts (30,139 females) were invited to a community-randomized HPV16/18-vaccination trial. A total of 9,482 female trial participants received HPV16/18-vaccination in 2007-2009 at age of 13-15. At age 22, 4,273 (45%) of these females consented to attend a randomized trial on frequent (ages 22/25/28; Arm 1: 2,073 females) vs. infrequent screening (age 28; Arm 2: 2,200 females) in 2014-2017. Females (1,329), who had got HPV16/18 vaccination at age 18 comprised the safety Arm 3. Baseline prevalence and incidence of HPV16/18 and other high-risk HPV types were: 0.5% (53/1,000 follow-up years, 10(4)) and 25% (2,530/10(4)) in the frequently screened Arm 1; 0.2% (23/10(4)) and 24% (2,413/10(4)) in the infrequently screened Arm 2; and 3.1% (304/10(4)) and 23% (2,284/10(4)) in the safety Arm 3. Corresponding prevalence of HSIL/ASC-H and of any abnormal cytological findings were: 0.3 and 4.2% (Arm 1), 0.4 and 5.3% (Arm 2) and 0.3 and 4.7% (Arm 3). Equally rare HSIL/CIN3 findings in the infrequently screened safety Arm A3 (0.4%) and in the frequently screened Arm 1 (0.4%) indicate no safety concerns on infrequent screening despite the up to 10 times higher HPV16/18 baseline prevalence and incidence in the former.
Subject: human papillomavirus
vaccination
screening
cervical intraepithelial neoplasia
cervical cancer
guidelines
CERVICAL-CANCER
INTRAEPITHELIAL NEOPLASIA
FOLLOW-UP
HPV
EFFICACY
CYTOLOGY
IMPACT
PREVENTION
INCREASE
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Baseline_findin ... virus_vaccinated_women.pdf 1.828Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record